Biofrontera AG - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 41
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: B9CCE93BCF1EN
Leaflet:

Download PDF Leaflet

Biofrontera AG – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Biofrontera AG – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Biofrontera AG – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Biofrontera AG human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Biofrontera AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Biofrontera AG’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Biofrontera AG’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Biofrontera AG in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Biofrontera AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Biofrontera AG.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Biofrontera AG and identify potential opportunities in those areas.
Biofrontera AG Snapshot
Biofrontera AG Overview
Key Information
Key Facts
Biofrontera AG – Research and Development Overview
Key Therapeutic Areas
Biofrontera AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Biofrontera AG – Pipeline Products Glance
Biofrontera AG – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Biofrontera AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Biofrontera AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Biofrontera AG – Drug Profiles
BF-200 ALA
  Product Description
  Mechanism of Action
  R&D Progress
BF-200 ALA
  Product Description
  Mechanism of Action
  R&D Progress
BF-derm1
  Product Description
  Mechanism of Action
  R&D Progress
BF-PC/13
  Product Description
  Mechanism of Action
  R&D Progress
BF-PC/18
  Product Description
  Mechanism of Action
  R&D Progress
BF-PC/21
  Product Description
  Mechanism of Action
  R&D Progress
Biofrontera AG – Pipeline Analysis
Biofrontera AG – Pipeline Products by Therapeutic Class
Biofrontera AG Pipeline Products By Target
Biofrontera AG – Pipeline Products by Route of Administration
Biofrontera AG – Recent Pipeline Updates
Biofrontera AG - Dormant Projects
Biofrontera AG – Locations And Subsidiaries
Head Office
Recent Developments
Sep 29, 2010: Biofrontera Reports EMA Confirms Successful Validation Of BF-200 ALA
Dec 02, 2009: Biofrontera Reports Preliminary Phase III Trial Results With BF-200 ALA
Nov 25, 2009: Biofrontera AG Announces Database Closure In Biofrontera's Phase III Trial With BF-200 ALA
Oct 08, 2009: Biofrontera Launches Belixos In Germany
Oct 08, 2009: Biofrontera Launches Belixos In Germany
Jul 27, 2009: Biofrontera Announces Phase II Clinical Trial Study Of BF-derm1 In Chronic Urticaria
Apr 29, 2009: Excellent Phase III Results Of Biofrontera’s BF-200 ALA Presented At Dermatology CongressA
Jan 29, 2009: Biofrontera Completes Patient Enrollment In Phase III Study With BF-200 ALA
Dec 19, 2008: Biofrontera AG Announces Excellent Phase III-Results With BF-200 ALA
Nov 21, 2008: Biofrontera AG Announces Completion Of Patient Enrollment For Its BF-derm1 In Chronic Urticaria
Financial Deals Landscape
Biofrontera AG, Deals Volume Summary, 2004 to YTD 2010
Biofrontera AG, Deals Summary By Region, 2004 to YTD 2010
Biofrontera AG, Deals Summary, 2004 to YTD 2010
Biofrontera AG Detailed Deal Summary
Asset Purchase
Biofrontera Acquires Rights Of Relieva From Canadian Prime Pharmaceuticals
Acquisition
Infinity Pharmaceuticals Acquires Biofrontera Discovery From Biofrontera
Equity Offering
Biofrontera Completes Rights Offering Of $4 Million
Biofrontera Enters Into Co-Marketing Agreement With DSE Healthcare Solutions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 41

LIST OF TABLES

Biofrontera AG – Pipeline by Therapy Area and Indication, 2010
Biofrontera AG – Pipeline by Stage of Development, 2010
Biofrontera AG – Monotherapy Products in Pipeline, 2010
Biofrontera AG – Filed, 2010
Biofrontera AG - Phase II, 2010
Biofrontera AG - Pipeline By Therapeutic Class, 2010
Biofrontera AG - Pipeline By Target, 2010
Biofrontera AG – Pipeline By Route of Administration, 2010
Biofrontera AG – Recent Pipeline Updates, 2010
Biofrontera AG - Dormant Developmental Projects, 2010
Biofrontera AG, Deals Summary, 2004 to YTD 2010
Biofrontera AG, Deals Summary by Region, 2004 to YTD 2010
Biofrontera AG, Deals Summary, 2004 to YTD 2010
Biofrontera Acquires Rights Of Relieva From Canadian Prime Pharmaceuticals
Infinity Pharmaceuticals Acquires Biofrontera Discovery From Biofrontera
Biofrontera Completes Rights Offering Of $4 Million
Biofrontera Enters Into Co-Marketing Agreement With DSE Healthcare Solutions 39

LIST OF FIGURES

Biofrontera AG – Pipeline by Therapy Area and Indication, 2010
Biofrontera AG – Pipeline by Stage of Development, 2010
Biofrontera AG – Monotherapy Products in Pipeline, 2010
Biofrontera AG – Pipeline By Therapeutic Class, 2010
Biofrontera AG - Pipeline By Target, 2010
Biofrontera AG – Pipeline By Route of Administration, 2010 21

Ask Your Question

Biofrontera AG - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: